Compare CNET & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNET | APVO |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 4.3M |
| IPO Year | 2009 | 2023 |
| Metric | CNET | APVO |
|---|---|---|
| Price | $1.27 | $2.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.4K | ★ 45.0K |
| Earning Date | 05-19-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $46,633,000.00 | $3,114,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 34.20 | N/A |
| 52 Week Low | $0.57 | $0.50 |
| 52 Week High | $2.78 | $10.70 |
| Indicator | CNET | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 45.88 | 25.45 |
| Support Level | $1.16 | $2.30 |
| Resistance Level | $1.44 | $4.84 |
| Average True Range (ATR) | 0.12 | 0.23 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 44.33 | 5.11 |
ZW Data Action Technologies Inc provides one-stop services for clients on its Omni-channel advertising, precision marketing, influencer marketing and data analysis management system. It also develops block-chain enabled web/mobile applications and provides Software-as-a-Service services for clients. In addition, it provides intellectual property licensing services. The company derives revenue from distributing the right to use search engine marketing service it purchased from key search engines to increase the sales conversion rate for clients business promotion on both mobile and computer searches; providing internet advertising and related marketing services for clients businesses; providing intellectual property licensing services; and providing Blockchain-based SaaS Services.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.